Search

Your search keyword '"Yalniz, Fevzi F."' showing total 20 results
Start Over Author "Yalniz, Fevzi F."
20 results on '"Yalniz, Fevzi F."'

1. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia

Author

Yalniz, Fevzi F., Saliba, Rima M., Greenbaum, Uri, Ramdial, Jeremy, Popat, Uday, Oran, Betul, Alousi, Amin, Olson, Amanda, Alatrash, Gheath, Marin, David, Rezvani, Katayoun, Hosing, Chitra, Im, Jin, Mehta, Rohtesh, Qazilbash, Muzaffar, Joseph, Jacinth Joy, Rondon, Gabriela, Kanagal-Shamanna, Rashmi, Shpall, Elizabeth, Champlin, Richard, and Kebriaei, Partow

Published
2021
Full Text
View/download PDF

2. CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity

Author

Greenbaum, Uri, Strati, Paolo, Saliba, Rima M., Torres, Janet, Rondon, Gabriela, Nieto, Yago, Hosing, Chitra, Srour, Samer A., Westin, Jason, Fayad, Luis E., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Nastoupil, Loretta J., Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Flowers, Christopher R., Tummala, Sudhakar, Ramdial, Jeremy L., Yalniz, Fevzi F., Hawkins, Misha, Rezvani, Katayoun, Champlin, Richard E., Shpall, Elizabeth J., Neelapu, Sattva S., Kebriaei, Partow, and Ahmed, Sairah

Published
2021
Full Text
View/download PDF

3. The Validation of Digital PCR–Based Minimal Residual Disease Detection for the Common Mutations in IDH1and IDH2Genes in Patients with Acute Myeloid Leukemia

Author

Di, Jing, Sheng, Tao, Arora, Ranjana, Stocks-Candelaria, Jennifer, Wei, Sainan, Lutz, Charles, Yalniz, Fevzi F., and Zhang, Shulin

Abstract

Accurate monitoring of minimal residual disease (MRD) is crucial for effective management of patients with acute myeloid leukemia (AML). This study aims to validate MRD detection of the seven most common IDH1and IDH2mutations in patients with AML using a QuantStudio 3D digital PCR platform. This assay demonstrated a high concordance for the variant allele frequencies between digital PCR and next-generation sequencing assays. Precision analysis revealed only small variation (<0.5 log10) for all mutations near or at the limit of detection level. This validation also showed a great reproducibility for interrun and intrarun comparisons (28 runs, variation ranges from 0 to 0.48 log10), ensuring comparable results for patient follow-ups. The limit of detection was determined to be 0.1% for all mutations, except the IDH2 R140Qmutation, which was 0.5%. Controls and acceptable ranges were also established for each mutation during validation. This study suggests that the QuantStudio 3D digital PCR assay is a quantitative, sensitive, and reproducible platform for monitoring MRD in patients with AML.

Published
2025
Full Text
View/download PDF

4. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation

Author

Yalniz, Fevzi F., Greenbaum, Uri, Pasvolsky, Oren, Milton, Denái R., Kanagal-Shamanna, Rashmi, Ramdial, Jeremy, Srour, Samer, Mehta, Rohtesh, Alousi, Amin, Popat, Uday R., Nieto, Yago, Kebriaei, Partow, Al-Atrash, Gheath, Oran, Betul, Hosing, Chitra, Ahmed, Sairah, Champlin, Richard E., Shpall, Elizabeth J., Qazilbash, Muzaffar H., and Bashir, Qaiser

Published
2024
Full Text
View/download PDF

5. Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients.

Author

Yalniz, Fevzi F., Johnson, Anna, Alnimer, Yanal, Chahine, Zena, Morris, Trevor, Yadav, Rina, Taj, Hiffsa, Iragavarapu, Chaitanya, Munker, Reinhold, Monohan, Gregory, Wai, Sainan, Zhang, Shulin, Nozad, Sahar, and Qasrawi, Ayman

Subjects
*ACUTE myeloid leukemia, *GENETIC profile, *OVERALL survival, *GENETIC mutation, *OBESITY
Abstract

ABSTRACT Background Methods Results Conclusions The molecular architecture of acute myeloid leukemia (AML) is heterogeneous. Obesity has been identified as a risk factor for the development of AML. There remains a scarcity of data elucidating the specific genetic profile of AML in obese patients.We conducted a review of adult patients treated at our institution for newly diagnosed AML from January 1, 2017, to January 1, 2023. Obesity is defined as BMI > 30 kg/m2. Demographic, clinical, laboratory, and pathologic data were collected retrospectively. The primary outcome of interest was the molecular features of obese compared to non‐obese AML patients. The secondary outcome was overall survival (OS). Inverse probability of treatment weights (IPTW) used to balance both groups on several confounding variables.A total of 185 patients were included in the analysis. 90 (49%) were obese. Compared with non‐obese patients, obese patients were younger and more likely to be females (55 vs. 63, p = 0.04, 55% vs. 38%, p value, p = 0.02, respectively). After matching on age, gender, and ethnicity, obese patients exhibit lower rates of total number of gene mutations (median 2.7 vs. 3.2, p = 0.05), significantly lower rates of mutations in transcriptional factor genes (15.7% vs. 33.2%, p = 0.01), and near‐significant in spliceosome genes (12% vs. 22.3%, p = 0.08), and higher rates of NPM1 mutation (23.3% vs. 12.6%, p = 0.08). Median OS was not significantly different in the matched cohort.The molecular features of obese AML patients significantly differ from non‐obese counterparts. These findings suggest distinct underlying mechanisms in leukemogenesis in obese patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation

Author

Yalniz, Fevzi F., primary, Greenbaum, Uri, additional, Pasvolsky, Oren, additional, Milton, Denái R., additional, Kanagal-Shamanna, Rashmi, additional, Ramdial, Jeremy, additional, Srour, Samer, additional, Mehta, Rohtesh, additional, Alousi, Amin, additional, Popat, Uday R., additional, Nieto, Yago, additional, Kebriaei, Partow, additional, Al-Atrash, Gheath, additional, Oran, Betul, additional, Hosing, Chitra, additional, Ahmed, Sairah, additional, Champlin, Richard E., additional, Shpall, Elizabeth J., additional, Qazilbash, Muzaffar H., additional, and Bashir, Qaiser, additional

Published
2023
Full Text
View/download PDF

14. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL)

Author

Greenbaum, Uri, primary, Strati, Paolo, additional, Saliba, Rima M., additional, Torres, Janet, additional, Rondon, Gabriela, additional, Nieto, Yago, additional, Hosing, Chitra, additional, Srour, Samer A., additional, Westin, Jason, additional, Fayad, Luis, additional, Lee, Hun Ju, additional, Iyer, Swaminathan P, additional, Nastoupil, Loretta J., additional, Parmar, Simrit, additional, Rodriguez, Maria Alma, additional, Samaniego, Felipe, additional, Steiner, Raphael Eric, additional, Wang, Michael, additional, Pinnix, Chelsea C., additional, Flowers, Christopher, additional, Tummala, Sudhakar, additional, Ramdial, Jeremy, additional, Yalniz, Fevzi F., additional, Hawkins, Misha, additional, Rezvani, Katayoun, additional, Champlin, Richard E., additional, Shpall, Elizabeth J., additional, Neelapu, Sattva S., additional, Kebriaei, Partow, additional, and Ahmed, Sairah, additional

Published
2020
Full Text
View/download PDF

15. Significance of minimal residual disease monitoring by real‐time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes

Author

Yalniz, Fevzi F., primary, Patel, Keyur P., additional, Bashir, Qaiser, additional, Marin, David, additional, Ahmed, Sairah, additional, Alousi, Amin M., additional, Chen, Julianne, additional, Ciurea, Stefan O., additional, Rezvani, Katy, additional, Popat, Uday R., additional, Shpall, Elizabeth J., additional, Champlin, Richard E., additional, and Oran, Betül, additional

Published
2020
Full Text
View/download PDF

16. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation

Author

Yalniz, Fevzi F., primary, Saliba, Rima M., primary, Yucel, Orhan K., primary, Garcia-Manero, Guillermo, primary, Ramdial, Jeremy, primary, Popat, Uday, primary, Ciurea, Stefan O., primary, Kebriaei, Partow, primary, Alousi, Amin M., primary, Alatrash, Gheath, primary, Bashir, Qaiser, primary, Hosing, Chitra, primary, Marin, David, primary, Mehta, Rohtesh, primary, Olson, Amanda L., primary, Rezvani, Katayoun, primary, Shpall, Elizabeth J., primary, Rondon, Gabriela, primary, Champlin, Richard E., primary, and Oran, Betul, primary

Published
2019
Full Text
View/download PDF

17. A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy

Author

Yalniz, Fevzi F., primary, Berdeja, Jesus G., additional, Maris, Michael B., additional, Lyons, Roger M., additional, Reeves, James A., additional, Essell, James H., additional, Patel, Prapti, additional, Sekeres, Mikkael, additional, Hughes, Amanda, additional, Mappa, Silvia, additional, and Garcia‐Manero, Guillermo, additional

Published
2019
Full Text
View/download PDF

18. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents

Author

Duchmann, Matthieu, primary, Yalniz, Fevzi F., additional, Sanna, Alessandro, additional, Sallman, David, additional, Coombs, Catherine C., additional, Renneville, Aline, additional, Kosmider, Olivier, additional, Braun, Thorsten, additional, Platzbecker, Uwe, additional, Willems, Lise, additional, Adès, Lionel, additional, Fontenay, Michaela, additional, Rampal, Raajit, additional, Padron, Eric, additional, Droin, Nathalie, additional, Preudhomme, Claude, additional, Santini, Valeria, additional, Patnaik, Mrinal M., additional, Fenaux, Pierre, additional, Solary, Eric, additional, and Itzykson, Raphael, additional

Published
2018
Full Text
View/download PDF

20. A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.

Author

Yalniz, Fevzi F., Berdeja, Jesus G., Maris, Michael B., Lyons, Roger M., Reeves, James A., Essell, James H., Patel, Prapti, Sekeres, Mikkael, Hughes, Amanda, Mappa, Silvia, and Garcia‐Manero, Guillermo

Subjects
*MYELODYSPLASTIC syndromes, *TERMINATION of treatment, *DISEASE progression, *BONE marrow, *ADVERSE health care events
Abstract

Summary: Hypomethylating agents (HMAs) are standard of care for higher‐risk myelodysplastic syndromes (MDS). However, less than half of patients achieve objective responses and most eventually lose their response. Pracinostat is a pan‐histone deacetylase inhibitor with demonstrated activity in advanced myeloid malignancies. This phase II study explored the benefit of adding pracinostat to HMAs in MDS patients who did not respond to single‐agent HMA treatment. The goal was to estimate the clinical improvement rate [complete remission (CR), marrow CR, partial response (PR) and haematological improvement]. Group 1 included patients with primary/secondary HMA failures; Group 2 included those who did not achieve response but had stable disease (SD) after single‐agent HMAs. Forty‐five patients (39 Group 1, 6 Group 2) received a median of 3 cycles. Among all patients, 1 (2%) had CR, 7 (16%) had marrow CR and 18 (40%) had SD; disease progression occurred in 3 (7%). Median overall survival was 5·7/5·6 months for Group 1/2. Grade ≥3 adverse events occurred in 38 patients (84%) leading to treatment discontinuation in 12 (33%). Adding pracinostat to HMAs did not improve outcomes in patients previously treated with HMAs. Frequent dose modifications/early discontinuation resulted in suboptimal drug exposure. A reduced pracinostat dose may improve tolerability and efficacy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results